The FDA is investigating a 'serious risk' of cancer linked to Novartis' spinal muscular atrophy gene therapy Zolgensma, following reports of tumor cases in children. This follows Novartis linking two tumor cases in children to the therapy.
Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.
Novartis confirmed that nine patients who received its spinal muscular atrophy gene therapy Zolgensma have developed tumors following treatment, with seven cases newly reported, raising serious safety concerns about the widely used pediatric drug.
Researchers from Rutgers and other universities analyzed hundreds of online reviews of lemborexant, a prescription insomnia medication, and found that approximately 25% of reviewers stopped or planned to stop taking the drug due to troubling side effects.
Sutter Health has implemented a review board system to more efficiently process referrals for anti-amyloid therapies that slow Alzheimer's disease progression, as demand for these treatments increases. The approach aims to streamline access to these disease-modifying treatments for eligible patients.
A phase 2 study presented in Vienna showed that SAR402663, a single intravitreal gene therapy injection for wet age-related macular degeneration, achieved a 97% reduction in treatment burden with positive efficacy and safety results. More than 90% of patients responded to the medium dose treatment.
The US FDA warned Amgen that a promotional video for its colorectal cancer drug Vectibix was misleading because it highlighted benefits while failing to adequately disclose serious safety risks and patient limitations. The warning letter was issued on Tuesday.
Bristol Myers Squibb disclosed that a multiple sclerosis patient died from septic pneumonia following zola-cel CAR-T treatment, linking prior adverse events to manufacturing reagent changes. The company plans to restart trials in early 2025.
A study published in JAMA Neurology found that multiple sclerosis patients treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, though the absolute risk remains low. The research compared rituximab to other MS treatments.
Par Health USA recalled 22 lots of Argatroban Injection 250 mg/2.5 mL after detecting particulate matter including cellulose, polystyrene, and possibly stainless steel in the product, posing risks of pulmonary emboli and organ damage.
The UK Medicines and Healthcare products Regulatory Agency has revoked the marketing authorization for Valneva's IXCHIQ chikungunya vaccine following a benefit-risk assessment by the Commission on Human Medicines. The decision caused Valneva shares to fall on Monday.
Inventia Healthcare Limited is voluntarily recalling over 13,000 bottles of chlorthalidone tablets nationwide due to failures in critical dissolution testing. The FDA has classified this as a Class II recall, indicating the medication could cause temporary or medically reversible adverse health consequences.
Merck announced that remigromig, a tri-specific antibody acquired in a $1.3 billion buyout, achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema. However, language regarding the drug's safety profile has raised concerns among analysts.
A nationwide Danish study found that oral menopausal hormone therapy is associated with elevated risk of venous thromboembolism regardless of dose, while high-dose oral forms also increased stroke and heart attack risk. Transdermal treatments showed no overall increase in thrombotic risk.
Celldex Therapeutics' barzolvolimab achieved what analysts called best-in-class efficacy results in two Phase 3 trials for chronic spontaneous urticaria, meeting all primary and key secondary endpoints. However, the trials also reported two life-threatening anaphylaxis cases, causing shares to drop 13-15% despite the positive efficacy data.
The European Medicines Agency has launched an investigation into injectable iron medicines after reports of severe hypophosphatemia leading to osteomalacia, including cases occurring after just one or two doses in patients without recognized risk factors.
The FDA halted testing of Regenxbio's gene therapy for Hunter Syndrome after spinal MRI scans detected abnormalities in five trial participants. This is the second clinical hold placed on a Regenxbio gene therapy program.
Two Republican members of the House of Representatives are urging the FDA to reject clinical data from China unless trial sites have been recently audited by the agency, following reports of three patient deaths in separate gene therapy clinical trials conducted in China.
Medical experts specializing in Prader-Willi syndrome flagged serious adverse events in patients taking Neurocrine Biosciences' drug Vykat XR, raising safety concerns about the treatment for the rare genetic disorder.
Vistagen announced topline results from a repeat dose study of fasedienol for acute treatment of social anxiety disorder, showing favorable safety and tolerability profiles along with efficacy signals across primary and secondary endpoints in both repeat and single dose administrations.
India's drug regulator has taken enforcement action against approximately 90% of inspected pharmaceutical facilities identified as high-risk under a nationwide quality initiative, as authorities intensify oversight amid increased global scrutiny of Indian-made drugs.
Lawsuits over vision loss risks from Saxenda (liraglutide) emerge as Medicare begins covering GLP-1 medications for seniors over 65, raising questions about proper usage and safety in older populations.
The New England Journal of Medicine retracted the main clinical trial used to approve Amgen's $500 million drug Tavneos, following allegations of data manipulation. The European Medicines Agency had previously recommended revoking the drug's approval over data integrity concerns.
ADC Therapeutics shares plunged 53% in premarket trading after a late-stage study of its blood cancer drug showed more deaths among treated patients, despite meeting its main goal. The safety signal represents a significant setback for the company's development program.
Swiss drugmaker Roche presented latest clinical trial data for its experimental multiple sclerosis drug at a major conference, setting the stage for regulatory approval submissions, though safety questions remain under scrutiny.